Global stockmarkets have added trillions of dollars on US biotech Moderna announcing cautious, but positive Phase I trials into a Covid-19 vaccine. The bigger question is whether this treatment, if proven, is enough to fix the long-term economic damage. Have the markets put euphoria ahead of sense again?